(PharmaNewsWire.Com, September 05, 2017 ) The North America Liquid Biopsy market is expected to increase at a CAGR of 19.6% in the forecast period of 2016-2021 and reach a value of USD 433.29 million by 2021 from USD 177.06 million in 2016. North America is leading market for Liquid Biopsy. Liquid biopsy market is on high growth in North America as colorectal cancer stands fourth most common diagnosed cancer in the region. There is a lot of research going on for the detection of colorectal cancer. Geographically North America Market is segmented into USA and Canada.
Liquid Biopsy market Growth is an emerging non-invasive procedure that can detect cancer at very advance stage. This is done by testing a sample of blood and detecting cancer cells from the tumour. Taking various samples of the blood helps doctors understand the behaviour of the tumour over time. This technique of detecting cancer is very valuable for the doctors using targeted therapies to treat cancer.
Rising demand for non-invasive procedures, greater accuracy to detect cancer cells and the increasing number of cancer cases are the key factors driving the liquid biopsy market. However, the unclear regulatory and reimbursement scenario is a major area of concern in the market.
The liquid biopsy market is mainly segmented by types of cancer into Lung Cancer, Pancreatic Cancer, Leukemia and Other Visceral Cancers. By Diagnostic approach they can be classified as Circulating Tumour cells (CTC), Circulating Tumour DNA (ctDNA), RNA in exosomes and Extra-Cellular Vesicles. Based on end users, the market is segmented into reference laboratories, hospital/physician laboratories, academic and research centers, and other end users.
The market is bifurcate into blood, urine, plasma, saliva and Cerebrospinal fluid based upon sample type. CTCs (Circulating Tumour cells), the first such entities on the liquid biopsy scene, have accounted for a large share in the market. Cancer institute is the largest end user segment in terms of revenues and is expected to create substantial opportunity in global liquid biopsy market over the forecast period.
The key players dominating the liquid biopsy market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
